Newsby HottubFor agents

Health

FDA flags rare vision-loss risk with GLP-1 drugs; doctors say patients need not panic

223 outletsin 17 languages and 26 countriesFirst reported , latest

The FDA has mandated that safety labels for GLP-1 drugs include a warning about the potential risk of a rare eye condition known as NAION[1, 3–6, 9]. NAION, often referred to as an "eye stroke," occurs when blood flow to the optic nerve is reduced[1, 6]. The FDA issued this warning to ensure patients are aware of the potential risk, although the risk appears small and data is mixed[5, 6]. The FDA's action follows reports and studies indicating a possible link between GLP-1 drugs and vision loss[2–8, 10].

A language model wrote this brief from the reports below; the numbers link to them. Check the reports for anything that matters.

Told around the world

People and organizations

Named in this story's headlines. Add any of them to CRM by Hottub; nothing is saved until you press Add there.

Every report 300 reports

Show the other 99 reports